1. Introduction {#sec1}
===============

Myelodysplastic syndromes (MDS) represent a heterogeneous spectrum of haematopoietic disorders ranging from ineffective haematopoiesis with cytopenia to progressive haematopoiesis with transition to acute myeloid leukaemia showing morphological and functional abnormalities of haematopoietic cells \[[@B1]--[@B3]\].

Due to difficulties in diagnosis and classification, epidemiological analyses report different incidence rates \[[@B4]\]. Nevertheless, it has been observed that intensive cancer therapeutic regimes lead to higher incidence rates of secondary forms of MDS \[[@B5]\]. As reviewed by Corey et al. \[[@B6]\] and Bernasconi \[[@B7]\], pathogenetic concepts favoured (i) chromosomal alterations and (ii) gain- and loss-of-function of proto-oncogenes and suppressor genes as well as (iii) disturbance of mitochondrial energy pathway and associated apoptosis. Although good progress was done to develop well-defined step-by-step pathogenetic models such as in colorectal cancer \[[@B8]--[@B11]\], the heterogeneous morphological spectrum and different clinical course of MDS remains poorly understood. Therefore, different subgroups of MDS with their characteristic cytogenetic, molecular, and immunological abnormalities were defined by international prognostic scoring systems such as the FAB (French American British) and the WHO classification to help to adequately stratify therapeutic regimens \[[@B1], [@B3], [@B12]\]. As described, the primary goal of treatment is haematological improvement in cases with low-risk MDS and targeting the underlying disease in cases with high-risk MDS \[[@B13]\]. Recently, experimental and clinical investigations revealed that epigenetic processes could play a key role in MDS and could be innovative targets for therapeutic approaches \[[@B14]--[@B18]\].

We therefore want to give a comprehensive survey of MDS in the frame of epigenetics with focuses on clinical, pathogenic, and therapeutic issues.

2. A Survey of Myelodysplastic Syndrome (MDS) {#sec2}
=============================================

2.1. A Short Introduction to the Definition, Classification (with Prognostic Groups), Epidemiology, and Aetiology {#sec2.1}
-----------------------------------------------------------------------------------------------------------------

According to the WHO, the myelodysplastic syndrome (MDS) is defined as a heterogeneous disease group with cytopenia due to ineffective haematopoiesis and with dysplastic morphological changes in one or more of the myeloid cell lineages and associated risk to progression into acute myeloid leukaemia \[[@B1]--[@B3]\].

Based on "characteristic" dysplastic features of haematopoietic cells (in the bone marrow as well as in the peripheral blood) \[[@B19]--[@B21]\] five "specific" subgroups of the MDS were distinguished \[[@B1], [@B22]\], which could be more sophistically subclassified by integrating specific cytogenetic investigations such as MDS with deletion of chromosome 5q done by the WHO in 2008 (as reviewed in detail \[[@B2], [@B3], [@B22]\]). Established MDS prognostic groups of low, intermediate I and II as well as of high risk (like the international prognostic scoring system (IPSS)) could identify the individual life risk and could be helpful for therapeutic decisions implementing blast count (according to the WHO classification), the number of cytopenias and cytogenetic findings \[[@B12]\] as well as parameter of red blood cell transfusion \[[@B23]\]. Interestingly, molecular alterations that are linked to specific signalling pathways of MDS like signalling and differentiation, cell cycle regulations, apoptosis, and translation are not integrated into the existing scoring system until now reflecting the morphological and molecular heterogeneity of this haematological entity \[[@B13], [@B22], [@B23]\].

MDS could be observed primarily de novo or after radiation or chemotherapy (especially in patients treated with alkylating agents or topoisomerase II inhibitors) as so-called secondary or therapy-associated form of MDS \[[@B5], [@B24]--[@B27]\]. Epidemiological data indicate that especially primary forms of MDS increase with the age of patients \[[@B28]\]: several authors reported an overall incidence rate of MDS ranging between 3.5 to 12.6 per 100,000 population per annum \[[@B29]--[@B31]\]. Ageing of the population in the Western world \[[@B32]--[@B34]\] and the extensive use of chemo- and radiotherapy for the treatment of malignant tumours \[[@B4], [@B24], [@B28], [@B35]\] will increase the incidence of MDS. Therefore, MDS becomes an important sociomedical issue, as epidemiological investigations revealed an age-specific increase of incidence between the age group of below 70 and above 70 years from 4.9 to 22.8 \[[@B36]\], 1.6 to 15.0 \[[@B30]\], or 15.0 to 49.0 \[[@B31]\], comparable to our own investigations \[[@B35]\].

As discussed above, the linkage between chemotherapy/radiotherapy and therapy-associated MDS is well known. Yet, knowledge about the aetiology of the large majority of de novo MDS is not fully conclusive, since some of the postulated risk factors for MDS (such as hair dyes, alcohol, and viral disease) showed only a weak or no association with MDS compared to accepted risk factors like solvents, cigarette smoking, and radiation \[[@B4], [@B37]\]. The inheritance of susceptibility genes is still unclear. Two commonly deleted segments, 5q31 and 7q22, were identified by cytogenetic analysis, which contains tumour-suppressor genes, and are therefore critical regions to MDS development, which could be inherited (germline) or induced by antitumour-therapy (somatic) as reviewed in \[[@B38], [@B39]\]. Finally, a small percentage of MDS in adults and in children is associated with genetic disorders such as Fanconi anaemia, Bloom syndrome, Diamond-Blackfan syndrome as well as Down syndrome, Shwachman-Diamond syndrome, and neurofibromatosis \[[@B6]\].

2.2. Pathogenetic Insights {#sec2.2}
--------------------------

As reviewed in detail by Corey et al. \[[@B6]\], Bernasconi \[[@B7]\] and Nimer \[[@B18]\] common and distinct pathways are involved in the pathogenesis of MDS, which could be summarized by (i) chromosomal/genetic alterations and molecular defects, (ii) disturbance of the microenvironment, and (iii) deregulation of apoptosis as discussed in detail below (see also [Figure 1](#fig1){ref-type="fig"}).

### 2.2.1. The Stem Cell Genetic Defect {#sec2.2.1}

Cytogenetic investigations revealed a broad range of defects which are linked to specific biological, clinical, and therapeutic features of MDS as reviewed in detail elsewhere \[[@B7]\]. Overall, chromosomal abnormalities could be detected in about 40--60% of primary and in about 70--90% of secondary forms of MDS ranging from balanced/unbalanced chromosomal rearrangements to specific chromosomal abnormalities such as Del(5q), −7, Del(7q), +8, Del(20q), −Y, 17p rearrangements, 11q23 translocations as well as complex karyotypes (≥3 defects) \[[@B7], [@B10], [@B39]\]. Compared to AML, more deletions and numerical defects than translocations were observed in MDS, which go along with nonclonal defects indicating a different pathogenesis in MDS compared to AML \[[@B41], [@B42]\]. The role of these chromosomal abnormalities for MDS still remains unclear, since "typical" class I and II mutations in the leukemic transformation of AML are missing in MDS \[[@B7], [@B10], [@B39]\], normal and abnormal karyotypes are observed side-by-side in bone marrow of patients with MDS and, finally, chromosomal aberrations are found more often in late than early stages of MDS \[[@B43]\].

Looking on molecular defects in MDS, multiple genes are affected such as CDKN2B, EVI1, IRF1, NRAS, TP53, FLT3, and MLL (in decreasing incidence according to \[[@B10]\]) by mutations, deletions, ectopic expression, or promoter methylation which could influence the expression of tumour suppressor genes, if genetic or epigenetic alterations of the other allele occurred as postulated by Knudson\'s hypothesis \[[@B44]\].

Based on the knowledge that the described genetic defect in MDS could be both somatic and/or germline-associated \[[@B45]--[@B47]\], the genetic heterogeneity of MDS demand for cytogenetic analysis in each individual case to evaluate the risk of heredity and of disease-progression as well as to develop better therapeutic options \[[@B48]\].

### 2.2.2. The Role of the Microenvironment {#sec2.2.2}

It was shown that abnormalities of the bone marrow microenvironment play a role in the pathogenesis of MDS by abnormal expression levels of cytokines such as interleukin 1*β*, interleukin 6, and tumour necrosis factor (TNF)-*α* \[[@B49], [@B50]\]. In detail, there is evidence that an enhanced TNF-*α* expression induced resistance of MDS cells to the proapoptotic effects of TNF-*α* leading to proliferation and progression \[[@B51]\]. Additionally, deregulation of proangiogenesis factors (like vascular endothelial growth factor (VEGF)) promotes an enhanced self-renewal and cytokine elaboration \[[@B52]\]. In contrast to the findings on VEGF, the expression of matrix metalloproteinases (MMP) (especially MMP2 and MMP9) in monocytes correlated with an increased apoptotic rate and longer overall survival in MDS patients \[[@B53]\].

### 2.2.3. Apoptosis Deregulation {#sec2.2.3}

Deregulation of apoptotic processes is mainly observed in early stages of MDS, whereas a deregulation of proliferation is found in advanced MDS. This is supported by the investigation of apoptosis-associated markers (ligands and receptors) as reviewed by Bernasconi \[[@B7]\]. In low-risk MDS, an upregulation of Apo 2.7, TRAIL, FAS/CD95, p38, TNFR1, CFLARs and Erk1/2 and downregulation of bcl-2, TNFR2, CFLAR~L~, NF-*κ*B, and AKT were found, whereas in high-risk MDS a diametric expression pattern was observed. Apoptosis can be influenced differentially by cytogenetic defects and by cytokine disarrangement of the stromal cell compartments. For instance, MDS associated with aneuplodies (such as three copies of chromosome 8) presents a significantly higher percentage of apoptotic CD34+ cells. Furthermore, MDS cells with isolated deletion of chromosome 5q showed a G~0~/G~1~ arrest through the antiproliferative effect of lenalidomide by the adjustment of growth and differentiation signals inside the bone marrow environment \[[@B42]\]. Finally, extrinsic apoptotic pathways could be deregulated by uncontrolled upregulation of apoptosis-associated proteins like FAS/CD95, TNF*α*, or TRAIL ligands \[[@B54]\].

### 2.2.4. Molecular Signals for MDS Progression towards AML {#sec2.2.4}

What are the essential molecular signals promoting MDS towards AML? Experimental findings investigating apoptotic deregulation suggest a continuous switch from predominant proapoptotic to a more proproliferative status of MDS cells \[[@B6], [@B7]\]. Transcriptional pathways essentially involved in this process are the RELA/NFKB1 and the PI3KC2A/AKT1 signal transduction axis \[[@B55], [@B56]\]. In short, proinflammatory cytokines (such as TNF*α*, TRAIL, and FAS/CD95) activate the CHUK/IKBKB complex with consecutive release and nuclear translocation of RELA and NFKB1 along with activation of genes being associated with cell growth, differentiation, inflammation, and apoptosis \[[@B7]\].

In summary, our knowledge of (i) these specific molecular abnormalities in the haematopoietic cells in MDS as well as of (ii) immune deregulation and of (iii) abnormal bone marrow environment in MDS is sophisticated \[[@B8]--[@B11]\] (see also [Figure 1](#fig1){ref-type="fig"}) and could not explain the heterogeneous morphological and clinical presentation of this complex disease. Additionally, mouse models of MDS currently available are not suited to reflect all of the features of MDS \[[@B57]--[@B59]\]. Taken together, the differentiation as well as proliferation/survival is impaired in MDS with potency to progression to AML due to an unknown second hit event \[[@B18]\].

2.3. Therapeutic Approaches {#sec2.3}
---------------------------

Standardised therapeutic stratifications were established depending on the prognostic subgroups and with respect to age and performance status of the patients (see also [Table 1](#tab1){ref-type="table"}). The therapeutic aims are: (i) a haematological improvement in low-risk and (ii) altering natural disease course in high-risk MDS disease subgroups. Additional information on clinical and molecular features (as mentioned above) will lead to a tailored, individualised decision management for therapy in future (see [Figure 1](#fig1){ref-type="fig"}).

Until now, internationally approved drugs to treat patients with MDS are erythropoietin, darbepoeitin, lenograstim (G-CSF), 5-azacytidine, decitabine, anti-thymocyte globulin, cyclosporine, lenalidomide, deferasirox, and deferoxamine \[[@B13]\].

In short, the mechanistic aspects of these currently available treatment options are explained.

i.  In the "best supportive care" setting erythropoietin, darbepoeitin and lenograstim (G-CSF) act as classical hematopoietic growth factors stimulating normal residual hematopoiesis, whereby additional effects of these drugs such as inducing differentiation of dysplastic hematopoiesis via blocking of apoptosis are discussed \[[@B63], [@B64]\].

ii. The chelation therapy with deferasirox and deferoxamine has the intention to reduce the transfusional iron overload associated with organ dysfunction due to chronic anaemia in MDS by mobilization of organ iron deposit and increased secretion of urinary iron \[[@B65], [@B66]\].

iii. Anti-thymocyte globulin, cyclosporine, and lenalidomide have similar immune modulatory properties interacting with deregulated lymphocytes (such as CD4/CD8 ratio or T-cell receptor repertoire) observed in MDS. Additionally, anti-thymocyte globulin and lenalidomide target changes in bone marrow microenvironment in MDS through antiangiogenic and antiproliferative capacities via modifying integrin and chemokine networks. Especially, lenalidomide has the property for direct clonal suppression of myelodysplastic clones with isolated deletion of chromosome 5q \[[@B41], [@B42], [@B67], [@B68]\].

iv. The transcriptional modifying therapy contains the two hypomethylating agents 5-azacytidine and decitabine. These two drugs are analogues of the pyramidine nucleoside cytidine and are integrated into RNA (5-azacytidine) or DNA (both), inducing progressive loss of methylation by covalently binding to DNA methyltransferases which are critical components of the epigenetic network inside normal and uncontrolled proliferation and differentiation \[[@B15], [@B69]\].

This heterogeneous list of drugs mirrors the different pharmacological approaches according to the stages and pathomechanisms of MDS. The development of new standardised guidelines for treatment of MDS as done by the National Comprehensive Cancer Network (NCCC) is therefore urgently needed (to view the most recent and complete version of the guidelines, see also <http://www.nccn.org/>) integrating ongoing response findings of clinical trials (e.g. based on epigenetic approaches \[[@B14], [@B16], [@B18], [@B70]\]).

### 2.3.1. Lower Risk MDS {#sec2.3.1}

According to the NCCC practical guidelines for patients with low-risk MDS, a supportive care for symptomatic anaemia and thrombocytopenia is mandatory to additional therapy depending on detectable genetic abnormalities. In cases of del(5q) and other cytogenetic abnormalities, treatment with lenalidomide is indicated. In case of no response and all other remaining cases, the decision of treatment with azacytidine, decitabine, antithymocytes globulin, cyclosporine, or again lenalidomide depends on the serum erythropoietin levels (\<\>500 mU/mL) as described in detail on the NCCC homepage. Additionally, the iron overload should be reduced by the use of iron chelators to reduce the risk of cardiac dysfunction.

### 2.3.2. Higher Risk MDS {#sec2.3.2}

According to the NCCC practical guidelines for patients with high-risk MDS, the intensity of treatment depends on the performance status of the patient and eligibility for allogenic haematopoietic stem cell transplantation (HSTT). Since the majority of patients with high-risk MDS are relatively old (\>70 yr), most of these patients are not possible candidate for high intensity induction chemotherapy and consecutive allogeneic HSTT and therefore receive azacytidine (preferred)/decitabine. The experience with allogeneic HSTT are disillusioning, since the response rate of allogeneic HSTT is generally low in comparison to de novo AML \[[@B71], [@B72]\]. Newer decision pathways for allogeneic HSTT as well as new induction regimes (such as reduced intensity conditioning) are in development to improve this high-intensity therapy \[[@B13]\].

Additionally, new therapies with heterogeneous pharmacological approaches for MDS are currently developed and investigated in ongoing clinical trials targeting selective pathways within the pathogenesis of MDS showing encouraging results and offering durable benefit to patients with MDS. These new drugs could be sorted according the targeted mechanism \[[@B70], [@B73], [@B74]\]: (i) interaction with survival signals such as antiangiogenesis, receptor tyrosine kinase inhibitors, protein kinase C inhibitors, matrix metalloprotease inhibitors, and farnesyl transferase inhibitors and (ii) interaction with genetic integrity such as immunoconjugate and P-glycoprotein antagonists.

Additionally, an alternative, potential, and promising approach could consist in the application of agents affecting epigenetic pathomechanisms, including histone deacetylase inhibitors (HDACi) such as vorinostat (SAHA), valproic acid, entinostat (MS275/SDX275), or panobinostat (LBH589). This class of agents (as discussed in detail below) are very interesting in the treatment of MDS, since HDACis reveal pleiotropic effects on cell cycle, differentiation, and apoptosis \[[@B75], [@B76]\] which are linked and deregulated in MDS.

3. Cancer, Epigenetics, and HDACi {#sec3}
=================================

3.1. Cancer and Epigenetic: A Short Overview {#sec3.1}
--------------------------------------------

Carcinogenesis is characterised by different sequential or parallel genetic/epigenetic hits with a gain- and/or a loss-of-function that leads to "hallmarks of cancer" such as proliferation, apoptosis, tissue remodelling, metastasis, and neoangiogenesis, as described in detail by Hanahan and Weinberg in an outstanding review \[[@B77]\]. In recent years, the importance of epigenetic alterations in carcinogenesis processes is emphasised and lead to the development of novel therapeutic approaches.

At a glance, epigenetic mechanisms include DNA methylation of cytosine residues inside CpG islands often found within transcriptional promoter regions in the DNA and various histone modifications leading to altered gene expression \[[@B78]--[@B80]\] (see also [Figure 2](#fig2){ref-type="fig"}).

3.2. The Role of Histone Modifications {#sec3.2}
--------------------------------------

Basic histone proteins H2a, H2b, H3, and H4 build an octamer, called nucleosome packing the DNA by coiling into the nucleus \[[@B81]\]. These histone complexes are posttranslationally modified by different levels of methylation, acetylation, phosphorylation, or ubiquitinylation in order to coordinate the regulation of gene transcription---a process referred to as "histone coding" \[[@B82]\]. These acyl modifications of histone proteins are exerted by two groups of highly conserved enzymes called histone acetyl transferases (HAT) and histone deacetylases (HDAC). HAT transfer acetyl groups to *ε*-amino groups of lysine residues in all four histone proteins leading to an "open" conformation of chromatin allowing subsequent binding of transcription factors, whereas the typical result of deacetylation by HDACs is condensed chromatin associated with transcriptional repression \[[@B83]\]. Interestingly, only 2 to 10 percent of all genes are regulated by this mechanism as demonstrated using gene arrays emphasizing the role of this "histone code" \[[@B76], [@B84], [@B85]\]. However, this data displayed the change in global gene expression, and these studies did not investigate single histone acetylation status or functional analysis of histone deacetylation.

Until now more than 30 different HATs have been described and have been divided into two main classes with different cellular distribution. Whereas A-type HATs are found in the nucleus and have a transcriptional role, B-type HATs are located in the cytoplasma \[[@B86], [@B87]\]. On the other side, at least 18 different HDACs have been published and are categorised into four major groups based on their sequence homology to their respective yeast HDACs \[[@B75], [@B88]\]: Class I---HDACs (Rpd3-like) with the zinc-dependent isotypes HDAC 1, 2, 3, and 8 are located in the nucleus and act as transcriptional corepressors. Class II---HDACs (Had1-like) with HDAC 4, 5, 6, 7, 9, and 10 are located in nucleus and cytoplasma and show also a transcriptional corepressor function but also mediate a variety of cytoplasmic nonhistone protein modifications \[[@B89]\]. Class III---HDACs (sirtuins) with SIRT1 to 7 are associated with regulation of cell proliferation and cell cycle control. Additionally, HDAC11 represents a separate class (class IV) of HDACs, since HDAC11 is structurally related to both, class I and II HDACs \[[@B90]\].

This subtype of epigenetic mechanisms of histone modification is centrally involved in the regulation of differentiation, proliferation, and tissue maintenance during embryogenesis \[[@B92], [@B93]\]. In contrast, deregulated epigenetic action of HDACs is observed in various types of human tumours such as gastric (HDAC1), breast (HDAC1, HDAC6), or colon carcinoma (HDAC3) \[[@B94]--[@B97]\]. Additionally, histone modifications are essentially involved in haematological diseases such as leukaemias as reviewed by Issa \[[@B16]\]. For that reason, the inhibition of HDACs generally seems to be a promising and novel approach in the treatment of human cancer.

3.3. Molecular Classes and Mechanisms of HDACi {#sec3.3}
----------------------------------------------

Many chemical substances have been developed to inhibit HDACs in vitro and in vivo which could be divided in hydroxamic acid derivates, cyclic tretapeptides, benzamides, and short-chain fatty acids as listed in [Table 2](#tab2){ref-type="table"}. Some of them are tested in clinical trials \[[@B83], [@B98]\], whereas until now only superoylanilide hydroxamic acid (SAHA) has received approval by the FDA for the treatment of cutaneous T-cell lymphoma \[[@B99]\].

In general, the effects of such HDACi are pleiotropic with induction of differentiation, growth arrest, and/or apoptosis of tumour cells \[[@B100], [@B101]\]. To evaluate the possible role of HDACi in MDS, it is necessary to look into the molecular mechanism of HDAC inhibition. Although the exact mechanisms of anticancer effect by HDACi are under debate, HDACi have both specific and unspecific effects \[[@B76], [@B83], [@B91]\]. With the exception of HDAC6 inhibitors, all HDACi induce a G~1~/S-phase cell cycle arrest associated with an increased expression of the endogenous cyclin-dependent kinase inhibitor p21^cip1/waf1^ \[[@B102], [@B103]\]. This action can be both p53-dependent and -independent as shown by our own experiments \[[@B104], [@B105]\]. For all other effects observed for HDACi such as upregulation of the death receptor pathway (extrinsic (TRAIL-mediated) and intrinsic (mitochondrial-related)), induction of reactive oxygen species, and alteration of chaperone function (part of the cellular stress response) or NF-*κ*B pathway (modulator of the inflammatory pathway), it is difficult to define if the effects of HDACi are directly triggered by transcriptional regulation that is mediated by hyperacetylation \[[@B89], [@B106]\]. Newer investigations revealed that acetylation and deacetylation represent an ubiquitous regulation mechanism for cellular networking such as RNA splicing, DNA damage repair, cell cycle control, nuclear transport, actin remodelling, ribosome, and chaperone function that is summarised as "acetylome" \[[@B107]--[@B110]\]. Additionally, HDACis influence posttranscriptional pre-mRNA processing and proteasomal and nonproteosomal pathways with heterogenous and different effect on ubiquitination \[[@B111]\], so that it is impossible to define a general mode of action for HDACi \[[@B89]\].

3.4. Clinical Application and Experience of HDACi {#sec3.4}
-------------------------------------------------

The majority of chemically designed HDACi is under intensive clinical investigation for treatment of haematological diseases such as acute or chronic leukaemias, lymphomas, and MDS \[[@B112], [@B113]\]. Currently, only the pan-deacetylase inhibitor SAHA has been approved by the FDA for treatment of cutaneous T-cell lymphoma (CTCL) \[[@B99]\]. Until now, the overall response reached up to 30%, but long-term surveillance is still missing. From a pharmacokinetic view most of HDACi used in clinical phase I studies have short half-life in plasma (2--8 hrs, except for MS-275 with 80 h \[[@B114]\]), followed by hepatic metabolism and intestinal excretion \[[@B115]--[@B120]\]. The major adverse toxicities of HDACi include fatigue, somnolence, confusion, diarrhoea, myelosuppression, and QT prolongation, thus limiting therapeutic applications \[[@B115]--[@B120]\]. Additionally, two questions regarding the use of HDACi are still unanswered. (i) It is currently unclear whether more specific HDAC class I & II inhibitors (like MS-275) or pan-deacetylase inhibitors (like SAHA or panobinostat) are more efficient in tumour reduction. (ii) Furthermore, is the acetylation of histone H3 in peripheral blood mononuclear cells a tool for biomarker HDAC inhibitor efficiency \[[@B115]\]? Various studies could not confirm a correlation of peripheral H3 acetylation and tumour treatment responses \[[@B112], [@B113]\]. Acetylation of peripheral H3 as well as expression of p21 in peripheral blood cells have been considered as potential biomarkers but were shown to possess only a poor correlation with the cognate expression pattern inside a (solid) tumour and with the overall response to the treatment. Additionally, an assay of HDAC enzymatic activity in intact cells on the basis of a cell-permeate substrate with fluorescent read-out was evaluated in two phase I trials, whereby the reliability of this test is not clear \[[@B118], [@B121]\]. For that, adequate biomarkers for monitoring tumour target effects of HDACi are still missing.

4. MDS, Epigenetics, and HDACi {#sec4}
==============================

It is still under debate how much epigenetics influences initiation and the clinical course of MDS. As mentioned above, experimental data suggest that especially DNA methylation plays an important role in the disrupted haematopoeisis \[[@B16]\]. In the progression of MDS, associated tumour suppressor genes are increasingly methylated, leading to resistance to classical cytotoxic chemotherapy \[[@B69]\]. For instance, methylation frequency of the tumour suppressor genes p15, CDH-1, DAP-Kinases, and SOCS-1 was detected in 89%, 48%, 28%, and 62% of patients with MDS, chronic myelomonocytic leukaemia, and high-risk AML, respectively \[[@B122]\]. Additionally, a genomics-based methylation assay of CD34+ cells of normal control patients and patients with MDS or AML revealed that more than 700 unique genes in CD34+ cells of MDS patients showed hypermethylation compared to normal controls \[[@B123], [@B124]\]. Recently, mutations of polycomb-associated gene ASXL1 which regulates histone modifications is described in MDS and chronic myelomonocytic leukaemia \[[@B125]\]. Nevertheless, "hard" data on the acetylation status in MDS are missing or are particularly published in circumstance of clinical trials of HDACi or in combination with DNA methyl transferase inhibitors (DNMTi), described below in detail.

4.1. Clinical Trials Phase I/II {#sec4.1}
-------------------------------

In 2001, the HDAC inhibitor valproic acid (VA) in combination with all-trans retinoic acid (ATRA) was shown to induce differentiation in malignant myeloid cells \[[@B126], [@B127]\] inducing the setup of different pilot studies of heterogeneous combination of these two drugs \[[@B17]\]. The response rate within these clinical trials reflects the morphological subtypes of MDS with overall response rates of 8%, 11%, 22%, and 50% in the line with MDS subgroups ranging from IPSS low-risk, intermediate-I, intermediate-II, to high-risk MDS, respectively. Interestingly, most of the responses were observed in the group with low-risk karyotypes \[[@B128]\].

In subsequent years, several clinical trials with other HDACi were started for therapy of MDS (as listed in [Table 3](#tab3){ref-type="table"}). Most of these clinical trials with HDACi are in phase I indicating the preliminary experience with these drugs in MDS. Specific or pan-HDACi were phenylbutyrate (partially in combination all-trans retinoic acid), depsipeptide (romidepsin), LBH589 (panobinostat), SAHA (Vorinostat), and MS275/SDX275 (entinostat) in descending order according to the frequency of use. As these trials were conducted in a Phase I setting, the overall patient number is low and the primary endpoints were toxicity and safety; response rates, ranging from 9 to 57%, were only secondary endpoints here.

An interesting aspect is the type of "biomarkers" which are used during these trials to describe the effects of HDACi on deacetylation \[[@B15], [@B17]\]: in the trials with valproic acid in combination with ATRA, the acetylation status of histone H3 and H4 in blood mononuclear cells as well as of the HDAC protein were determined. While missing other possibilities of sufficiently monitoring the bioactivity of HDACi, clinical effects such as transfusion requirements, white blood cell count, or percentage of immature cells (in the peripheral blood or bone marrow) were additionally used.

In summary, single agent clinical trials of HDACi have shown a good safety profile in patients with MDS, although the response rates observed so far are lower than for DNMT inhibitors, which is attributable to the predominant Phase I trial design conducted so far.

4.2. Combination Therapy {#sec4.2}
------------------------

Experimental data could demonstrate that DNA methylation interacts with histone deacetylase activity indicating the recursive complexity of epigenetics \[[@B129], [@B130]\]. Therefore, it was expected that HDACi and DNMTi would show synergistic effects \[[@B69], [@B131]\]. This synergistic effects could be explained by the known crosstalk between DNA methylation and histone modifications: (i) HDACs are activated by DNMT and by methylcytosine-binding proteins potentiating the gene silencing effect \[[@B78], [@B134]\], (ii) hypermethylated genes are resistant to re-expression by treatment with HDACis \[[@B135]\], and additionally (iii) DNMTi increases histone methylation and acetylation (such as H3K4) thus activating gene transcription \[[@B136]\]. Nevertheless, more detailed mechanisms of the synergistic effects of HDACi and DNMTi remain to be investigated. Our own experience with the DNMTi Zebularine and SAHA confirmed the synergy on apoptosis, proliferation inhibition, and differentiation in a pancreatic cancer model \[[@B132]\]. Therefore, analysis of sequential application of DNMTi and HDACi were performed in vitro and in vivo identifying that primary application of demethylating agent (low dose) following by an HDAC inhibitor show the best re-expression levels of hypermethylated genes \[[@B131], [@B133]\], which is in line with the concept of DNA methylation via the so-called de novo DNA methyltransferases during DNA replication \[[@B105]\].

Interestingly, combination therapy of MDS using DNMTi and HDACi is already ongoing (as listed in [Table 4](#tab4){ref-type="table"}) using the combination of decitabine or azazytidine as DNMTi and VA (in one study in combination with ATRA) or phenylbutyrate as HDACi. The overall response rates are optimistic up to 54%, whereas complete response was observed in up to 22%. Nevertheless, the patient numbers of these clinical trials are small due to the Phase I/II setting and are therefore not powered for determining response rates. No unexpected toxicity profiles were seen. Specific details of these studies were in detail: the study of Gore et al. showed that reversed methylation during the first cycle of therapy correlates with therapy response. Interestingly, this was more often accompanied by induction of acetylation of histone H3 and H4 following administration of the DNMTi rather than of the HDACi \[[@B137]\]. Such convincing data could not be obtained using the HDAC inhibitor VA. In the study of Garcia-Manero et al., global methylation and p15 promotor methylation did not differ between responders and nonresponders. Looking at HDACi effects, histone acetylation did not increase until application of highest dose level of VA, whereas the HDACi target p21^WAF1/CIP1^ increased during therapy \[[@B138]\]. Clinical benefit was observed in the trial of Blum et al. independently of whether with or without VA, confirming that this agent is not a potent HDACi \[[@B139]\]. Finally, the data of the study of Soriano et al. corroborated the findings of the other studies with VA that global mutation as well as induction of p21 and p14 mRNA did not correlate with therapy response \[[@B140]\].

In summary, the combination of HDACi with DNMTi as well as other combinations (including different cytotoxics, targeted therapies and radiation therapy as reviewed from Batty et al. \[[@B14]\]) still remains an interesting field for experimental investigations as well as for larger randomised trials based on available preclinical data in order to detect the best synergy of these agents.

5. Conclusion and Outlook {#sec5}
=========================

The heterogeneous nature of MDS demands differential therapy strategies, which reflects on the one hand prognostic subgroups, age, and performance status of the patients with MDS and on the other hand the associated pathogenesis pathways (see [Figure 1](#fig1){ref-type="fig"} and [Table 1](#tab1){ref-type="table"}). Until now, detailed insights into the pathogenesis of MDS have not been published. Yet, the factors driving progression as well their mechanism of interaction are still unclear. New insights came from the field of epigenetics, which admittedly leads to more complexity, too. First clinical trials give evidence that patients with MDS could benefit from epigenetic treatment with DNA methylation inhibitors and HDACi \[[@B14]\]. Nevertheless, many issues of HDACi remains completely unknown and pose clinical and translational challenges \[[@B76]\].

i.  As HDACi have been approved in the treatment of CTCL by the FDA, the mechanism of their selectivity is speculative postulating preferential induction of apoptosis in vitro \[[@B141]\], expression of HDAC2 in aggressive CTCL \[[@B142]\] as well as modulation of gene expression in vivo \[[@B143]\]. For that, further detailed molecular investigations of HDACi treated CTCL are urgently needed to better understand the molecular mechanisms of the reported excellent clinical results in CTCL and to confer these findings to other tumorous diseases like MDS.

ii. As histone H3 and H4 acetylation are not correlated with clinical response \[[@B112], [@B113]\], surrogate markers have to be identified for therapy prognosis, controlling and terminating related to the patient and MDS-related disease stage.

iii. An additional task is to clarify specific pharmacological aspects of HDACi such as potency, isotype selectivity, application, and toxicity profile as well as mechanisms of resistance. These findings could support the decision on which HDACi are suitable for which MDS subgroups \[[@B144]--[@B147]\].

iv. Finally, the sequential application strategy of HDACi with DNMTi or other cytotoxic drugs should be determined to optimize the additive or synergistic effects in the treatment of MDS \[[@B14]\].

For that, we are at the beginning of establishing a HDAC-inhibitor strategy in the complexity of therapeutic management of MDS.
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###### 

Therapeutic strategies in MDS depending of risk stratifying (adapted from \[[@B148], [@B149]\]).

                                                                  Low-risk MDS                                                         High-risk MDS
  --------------------------------------------------------------- -------------------------------------------------------------------- ---------------------------
  Survival                                                        3--10 years                                                          \<1.5 years
  Risk of AML transformation                                      Low rate                                                             High rate
  WHO entities                                                    RA, RARS, RCUD, RCMD, MDS-U, MDS del(5q)                             RAEB (−1, −2)
  IPSS Score (see \[[@B12]\])                                     Low, Int-1 (score 0-1.0)                                             Int-2, high (score ≥ 1.5)
  Approved and applied drugs/therapies                            Growth factors: Erythropoietin, G-CSF                                Decitabine, 5-azacitidine
  Immune therapy: steroids, cyclosporin, antithymocyte globulin   Investigational                                                      
  Lenalidomide: 5q31                                              Intensive chemotherapy                                               
  Decitabine, 5-azacitidine                                       (Younger, karyotype diploid), allogeneic stem cell transplantation   
  Iron chelation                                                  Iron chelation                                                       
  Translocation (5;12) or 5q23                                    Translocation (5;12) or 5q23                                         
  variant (PDGFR-B): Imatinib                                     variant (PDGFR-B): Imatinib                                          
  Future therapeutic perspectives                                 Combination with specific HDAC-Inhibitors                            

Abbrevations. AML: acute myeloid leukaemia; G-CSF: granulocyte-colony-stimulating factor; IPSS: International Prognostic Scoring System; MDS-U: MDS unclassifiable; MDS del(5q): MDS associated with isolated deletion of chromosome 5q; PDGFR-B: platelet-derived growth factor receptor B; RA: refractory anemia; RAEB: RA with excess blasts; RARS: RA with ring sideroblasts; RCMD: refractory cytopenia with multilineage dysplasia; RCUD: refractory cytopenia with unilinease dysplasia.

###### 

Selected HDAC inhibitors: structural class, compound, isotype selectivity, and study phase---an overview (according to Batty et al. \[[@B14]\] and Schneider-Stock and Ocker \[[@B83]\]).

  Structural                                                       HDAC inhibitor (synonyms, abbreviation, supplier)   Class selectivity     Study phase
  ---------------------------------------------------------------- --------------------------------------------------- --------------------- -------------
  Hydroxamic acids                                                 m-carboxycinnamic acid bis-hydroxamide (CBHA)                             
  Oxamflatin                                                                                                                                 
  Belinostat (PXD-101, Curagen Corp/TopoTarget A/S)                I, IIa, IIb, IV                                     II                    
  Pyroxamide                                                                                                           I                     
  Scriptaid                                                                                                                                  
  Superoylamilide hydroxamic acid (SAHA, Vorinostat)               I, IIa, IIb, IV                                     FDA approval (CTCL)   
  Trichostatin A (TSA)                                             I, II                                                                     
  Panobinostat (LBH-589; Novartis AG)                              I, IIa, IIb, IV                                     II                    
                                                                                                                                             
  Cyclic tretapeptides                                             Apicidin                                            I, II                 
  Romidepsin (FK-228, FR-901228; Gloucester Pharmaceuticals Inc)   I, II                                               II                    
  Trapoxin-histone acetylase (TPX-HA) analog (CHAP)                                                                                          
  Trapoxin                                                                                                                                   
                                                                                                                                             
  Benzamides                                                       Tacedinaline (CI-994; Pfizer Inc)                                         
  Entinostat SNDX-275 (MS-275; Syndax Pharmaceuticals Inc)         I, II                                               II                    
                                                                                                                                             
  Short-chain fatty acids                                          Butyrate                                            I, IIa                I
  Valproic acid                                                    I, IIa                                              I                     

###### 

Clinical trials of HDACi in MDS and AML (adapted and extended from \[[@B15], [@B17]\]; see also current and ongoing clinical trials at <http://www.clinicaltrials.gov/>).

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author (year)                             HDACi substance         Phase   Schedule                                                 Patient number   Diagnosis: patient number                   Responses\                                    Toxicity
                                                                                                                                                                                                  (i) overall \[%\]\                            
                                                                                                                                                                                                  (ii) details                                  
  ----------------------------------------- ----------------------- ------- -------------------------------------------------------- ---------------- ------------------------------------------- --------------------------------------------- -------------------------------------------------------------
  Gore et al. (2001) \[[@B150]\]            Phenylbutyrate          I       i.v., 125--500 mg/kg/day 7/28 days continuous infusion   27               MDS: *n* = 11, AML: *n* = 16                8 \[30%\]\                                    CNS toxicity, hypocalcemia, nausea/vomiting
                                                                                                                                                                                                  4 HI, 4 decline of PB blasts                  

  Gore et al. (2002) \[[@B151]\]            Phenylbutyrate          I       i.v., 375 mg/kg/day 7/14 or 21/28 days cont. infusion    23               MDS: *n* = 9, AML: *n* = 14                 2 \[9%\]\                                     CNS toxicity, skin reaction, hypo-calcemia
                                                                                                                                                                                                  2 HI (21/28 schedule)                         

  Zhou et al. (2002) \[[@B152]\]            Phenylbutyrate + ATRA   I       i.v., 200--400 mg/kg/day 25 days                         5                AML M3: *n* = 5                             1 \[20%\]\                                    Transient CNS depression
                                                                                                                                                                                                  1 RT-PCR neg. CR                              

  Odenike et al. (2006) \[[@B153]\]         Depsipeptide            II      i.v., 18 mg/m^2^/dayday 1, 8 and 15 every 28 days        18               AML: *n* = 18                               2 \[11%\]\                                    Nausea, vomiting, fatigue
                                                                                                                                                                                                  2 BM- blast clearance (t(8;21) and t(4;21))   

  Byrd et al. (2005) \[[@B154]\]            Depsipeptide            I       i.v., 13 mg/m^2^ day 1, 8, 15 every 28 days              10               AML: *n* = 10                               Transient declines in PB and BM blasts        Fatigue, vomiting, nausea, tumor lysis syndrome, diarrhea

  Giles et al. (2006) \[[@B155]\]           LBH589                  I       i.v., 4.8--14 mg/m^2^, days 1--7 every 21 days           14               AML: *n* = 13, MDS: *n* = 1                 8 \[57%\]\                                    QT-prolongation, nausea, vomiting, hypokalemia
                                                                                                                                                                                                  8 patients transient decline in PB blasts     

  Garcia-Manero et al. (2005) \[[@B156]\]   Vorinostat (SAHA)       I       Oral, 100--300 mg 2-3 ×/day, 14/21 days                  35               AML: *n* = 31, MDS: *n* = 3, CML: *n* = 1   9 \[25%\]\                                    Nausea, vomiting, diarrhea, neutropenia, typhlitis, fatigue
                                                                                                                                                                                                  1CR, 2CRp, 1PR, 5 complete marrow responses   

  Gojo et al. (2007) \[[@B157]\]            MS-275                  I       Oral, 4--10 mg/m^2^, 1 ×week for 2 or 4 weeks            38               AML: *n* = 38                               7 \[18%\]\                                    CNS toxicity, infections, fatigue, nausea, vomiting
                                                                                                                                                                                                  7 HI, transient decline in PB and BM blasts   
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations. AML: acute myeloid leukaemia; ATRA: All-trans-Retinoic-Acid; BM: bone marrow CML: chronic myelogenous leukaemia; CNS: central nervous system; CR: complete remission; CRp: complete response with incomplete platelet recovery; HDACi: histone deacetylase inhibitors; HI: haematologic improvement; MDS: myelodysplastic syndrome; PB: peripheral blood; PR: partial response.

###### 

Clinical trials of combination regimen with DNMTi and HDACi (adapted and extended from \[[@B15], [@B17]\]; see also current and ongoing clinical trials at <http://www.clinicaltrials.gov/>).

  Author (year)                             Schedule                                                                                Patient number                                                                    Diagnosis: patient number   Response *n* \[%\]                          Toxicity                                                        
  ----------------------------------------- --------------------------------------------------------------------------------------- --------------------------------------------------------------------------------- --------------------------- ------------------------------------------- ---------- ---------- -------- --------- ---------------------- --------------------------------------------------------------------------------
  Garcia-Manero et al. (2006) \[[@B138]\]   DAC 15 mg/m^2^ days 1--10+                                                              VA orally 20, 35, 50 mg/kg (days 1--10)                                           54                          AML: *n* = 48 MDS: *n* = 6                  12 (22%)   10 (19%)   2 (3%)                                    CNS toxicity
  Soriano et al. (2007) \[[@B140]\]         AZA 75 mg/m^2^ day 1--7+                                                                VA orally 50, 62, 5 and 75 mg/kg (days 1--7) + ATRA 45 mg/m^2^/ day (days 3--7)   53                          AML: *n* = 49 MDS: *n* = 4                  22 (41%)   12 (22%)   3 (5%)             7 (13%) BM responses   CNS toxicity
  Maslak et al. (2007) \[[@B158]\]          AZA 75 mg/m^2^ days 1--7+                                                               PB 200 mg/kg for 5 days after AZA                                                 10                          AML: *n* = 8 MDS: *n* = 2                   3 (30%)                        3 (30%)                          CNS toxicity, fever, nausea, fatigue
  Blum et al. (2007) \[[@B139]\]            DAC 20 mg/m^2^ days 1--10+                                                              VA escalating doses (days 5--21) 15, 20 or 25 mg/kg                               11                          AML: *n* = 11                               6 (54%)    2 (18%)             2 (18%)   2 (18%)CRi             CNS toxicity, myelosuppre ssion, infection, myeloid differentiation syndrome
  Gore et al. (2006) \[[@B137]\]            AZA 50 mg/m^2^ days 1--14, 1--10 or 1--5; 75 mg/m^2^ days 1--5; 25 mg/m^2^ day 1--14+   PB 375 mg/kg/day for 7 days after AZA                                             32                          AML: *n* = 18 MDS: *n* = 13 CMML: *n* = 1   11 (38%)   4 (14%)             1 (3%)    6 (21%) HI             CNS toxicity, mild nausea, injection sidereactions, asthenia, myelosuppression

Abbreviations. AML: acute myeloid leukaemia; ATRA: all-trans-Retinoic-Acid; AZA: azazytidine; CMML: chronic myelomonocytic leukaemia; CNS: central nervous system; CR: complete remission; CRi: complete responses with incomplete blood count recovery; CRp: complete response with incomplete platelet recovery; DAC: decitabine; DNMTi: DNA methyl transferase inhibitors; HDACi: histone deacetylase inhibitors; HI: haematologic improvement; MDS: myelodysplastic syndrome; PB: phenylbutyrate; VA: valproic acid.
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